Bibliographie : Cannabinoïdes et Maladies Neurodégénératives

GRECC > Publications > Bibliographies > Bibliographie : Cannabinoïdes et Maladies Neurodégénératives
20 janvier 2019 GRECC 0

Bibliographie CANNABINOIDES et Maladies Neurodégénératives

Dr Christian Sueur, GRECC, avril 2019 (2e édition).

 

  1. ALTAMURA C. et al. : Elevation of Plasma 2 –Arachidonoylglycerol Levels in Alzheimer’s Disease Patients as a Potential Protective Mechanism against Neurodegenerativ Decline, Journal of Alzheimer Disease, 2015, 46, 2, 497-506.
  2. ASO E., SANCHEZ-PLA A., VEGAS-LOZANO, MALDONADO R., FERRER I. : Cannabis-based medicine reduces multiple pathological process in AβPP/PS1 mice, Journal of Alzheimer’s Disease, 2015, 43, 977-991.
  3. ASO E. et al. : Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model, Journal of Alzheimer Disease, 2016, 54, 3, 903-912.
  4. BISOGNO T., ODDI S., PICCOLI A., FAZIO D., MACCARRONE M. : Type-2 cannabinoid receptors in neurodegeneration, Pharmacological Research, 2016, 111, 721-730.
  5. BILKEI-GORZO A., ALBAYRAM O., DRAFFEHN A., MICHEL K., PIYANOVA A., OPPENHEIMER H., DVIR-GINZBERG M., RACZ I., ULAS T., IMBEAULT S., BAB I., SCHULTZE J.L., ZIMMER A., : A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice, Nature Medicine, 2017, 23, 782-787. DOI : 10.1038/nm.4311
  6. FERNANDEZ-RUIZ J., GONZALES S., ROMERO J., RAMOS J.A. : Cannabinoids in neurodegeneration and neuroprotection, in « Cannabinoids as Therapeutics », Ed. R. Mechoulam, Birkhäuser Verlag, Switzerland, 2005, 79-109.
  7. FERNANDEZ-RUIZ J., SAGREDO O., PAZOS R., GARCIA C., PERTWEE R., MECHOULAM R., MARTINEZ-ORGADO J. : Cannabidiol for neurodegenerative disorders : important new clinical appplications for this phytocannabinoid ?, British journal of Clinical Pharamacology, 2012, 75, 2, 323-333.
  8. FERNANDEZ-RUIZ J., ROMERO J., RAMOS J.A. : Endocannabinoids and Neuro-degenerative Disorders : Parkinson’s Disease, Huntington’s Chorea, Alzheimer’s Disease and others, Handbook of Experimental Pharmacology, 2015, 231, 233-59.
  9. FOX S.H., KELLETT M., MOORE A.P., CROSSMAN A.R., BROTCHIE J.M. : Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia, Movement Disorders, 2002, 17, 145-149.
  10. FRIEDMAN D., FRENCH J.A., MACCARRONE M. : Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders, Lancet Neurology, 2019, Doi : 10.1016/S1474-4422(19)30032-8
  11. LIM K., SEE Y.M., LEE J. : A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative disorders, Clinical Psychopharmacology and Neuroscience, 2017, 15, 4, 301-312.
  12. MACCARRONE M., BERNARDI G., FINAZZI AGRO A., CENTONZE D. : Cannabinoid receptor signalling in neurodegenerative diseases : a potential role for membrane fluidity disturbance, British Journal of Pharmacology, 2011, 163, 1379-1390. DOI : 10.111/j.1476-5381.2011.01277.x
  13. MANNUCCI C., NAVARRA M., CALAPAI F. et al. : Neurological Aspects of Medical Use of cannabidiol, CNS & Neurological Disorders – Drug Targets, 2017, 16, 13 pp.
  14. MARTIN-MORENO A.M, BRERA B., SPUCH C. et al. : Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β–amyloid levels and improves cognitive performance in Tg APP 2576 mice, Journal of Neuroinflammation, 2012, 9, 8, 15 pp.
  15. MILTON N.G. : Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide, Neuroscience Letters, 2002, 332, 2, 127-130.
  16. PASSMORE M.J. : The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation, International Journal of Geriatric Psychiatry, 2008, 23, 1, 116-117.
  17. SHELEF A. et al. : Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia : An Open Label, Add-On, Pilot Study, Journal of Alzheimer Disease, 2016, 51, 1, 15-19.
  18. WALTHER S., MAHLBERG R., EICHMANN U. et al. : Delta-9-tetrahydrocannabinol for night-time agitation in severe dementia, Psychopharmacology (Berl), 2006, 185, 4, 524-528.
  19. WOODWARD et al. : Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms, American Journal of Geriatric Psychiatry, 2014, 22, 4, 415-419.
  20. ZIPP F., AKTAS O. : The brain as a target of inflammation : common pathways link inflammatory and neurodegenerative diseases, Trends in Neurosciences, 2006, 29, 518-527.

 

Cannabinoïdes et Maladie de Parkinson

  1. BALASH Y., BAR-LEV SCHLEIDER L., KORCZYN et al. : Medical Cannabis in Parkinson Disease : Real-Life Patients Experience, Clinical Neuropharmacology, 40, 6, 268-272.
  2. CAROLL C.B., BAIN P.G., TEARE L. et al. : Cannabis for dyskinesia in Parkinson’s disease : a randomised double-blind crossover study, Neurology, 2004, 63, 7, 1245-1250.
  3. CHAGAS M.H., ZUARDI A.W., TUMAS V., PENA-PEREIRA M.A. et al. : Effects of cannabidiol in the treatment of patients with Parkinson’s disease : an exploratory double-blind trial, Journal of Psychopharmacology, 2014, 28, 11, 1088-1098.
  4. FOX S.H., HENRY B., HILL M. et al. : Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson’s disease, Movement Disorders, 2002, 17, 6, 1180-1187.
  5. FRANKEL J.P., HUGHES A., LEES A.J., STERN G.M. : Marijuana for Parkinsonian tremor, Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 436.
  6. GARCIA C., PALOMO-GARO C., GARCIA-ARENCIBIA M., RAMOS J.A., PERTWEE R.G., FERNANDEZ-RUIZ J. : Symptom-relieving and neuroprotective effects of the phytocannabinoid delta9-THC in animal models of Parkinson’s disease, British Journal of Pharmacology, 2011, 163, 1495-1506. DOI : 10.1111/j.1476-5381.2011.01278.x
  1. GROTENHERMEN F. : Chanvre en Médecine. Redécouverte d’une plante médicinale. Guide pratique des applications thérapeutiques du Cannabis, du THC et du CBD, Edition Solanacée, 2017, « Maladie de Parkinson » p 102.
  2. HA A.D., JANKOVIC J. : Pain in Parkinson’s disease, Movement Disorders, 2012, 27, 4, 485-491.
  3. LASTRES-BECKER I., MOLINA-HOLGADO F., RAMOS J.A., MECHOULAM R., FERNANDES-RUIZ J. : Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro : Relevance to Parkinson’s disease, Neurobiology of Diseases, 2005, 19, 96-107.
  4. LOTAN I. TREVES T.A., RODITI Y., DJALDETTI R. : Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease : an open-label observationnel study, Clin Neuropharmacological, 2014, 37, 2, 41-44.
  5. MORE S.V., CHOI D.K. : Promising cannabinoid-based therapies for Parkinson’s disease : motor symptoms to neuroprotection, Molecular Neurodegeneration, 2015, 10, 17.
  6. PABON M.M., BACHSTETTER A.D., HUDSON C.E. et al : CXCL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson’s disease, Journal of Neuroinflammation, 2011, 8, 9.

https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-8#Sec9_511

  1. SIERADZAN K.A., FOX S.H., DICK J., BROTCHIE J.M. : The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson’s disease, Movement Disorders, 1998, 13 (supl 2) 29.
  2. SIERADZAN K.A., FOX S.H., HILL M., DICK J.P.R., CROSSMAN AR, BROTCHIE J.M. : Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease : A pilot study, Neurology, 2001, 57, 2108-2111.

 

Cannabinoïdes et Maladie de Huntington

  1. CONSROE P. et al. : Controlled clinical trial of cannabidiol in Huntington’s disease, Pharmacology Biochemistry and Behavior, 1991, 40, 3, 701-708.
  2. LOPES-SENDON MORENO J.L., GARCIA CALDENTEY J. et al. : A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease, Journal of Neurology, 2016, 263, 7, 1390-1400.
  3. SAFT C., Von HEIN S.M., LÜCKE T., THIELS C. et al. : Cannabinoids for Treatment of Dystonia in Huntington’s Disease, Journal of Huntington’s Disease, 2018, 7, 2, 167-173.
  4. SAGREDO O., PAZOS M.R., VALDEOLIVAS S., FERNANDEZ-RUIZ J. : Cannabinoids : novel medicines for the treatment of Huntington’s disease, Recent Patent in CNS Drug Discovery, 2012, 7, 1, 41-48.
  5. VALDEOLIVAS S., SATTA V., PERTWEE R.G., FERNANDEZ-RUIZ J., SAGREDO O. : Sativex-Like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned rats, an Inflammatory Model of Huntington’s Disease : Role of CB1 and CB2 Receptors, ACS Chemical Neuroscience, 2012, 3, 400-406.
  6. VALDEOLIVAS S., SAGREDO O., DELGADO M. et al. : Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease, International Journal of Molecular Sciences, 2017, 18, 684, 12 pp.

 

Cannabinoïdes et Maladie d’Alzheimer

  1. ALTAMURA C. et al. : Elevation of Plasma 2 –Arachidonoylglycerol Levels in Alzheimer’s Disease Patients as a Potential Protective Mechanism against Neurodegenerativ Decline, Journal of Alzheimer Disease, 2015, 46, 2, 497-506.
  2. ASO E., FERRER I. : Cannabinoids for treatment of Alzheimer’s disease : moving toward the clinic, Frontiers in Pharmacology, 2014, 5, 37, 11 pp.
  3. ASO E., FERRER I. : CB2 Cannabinoid Receptor as Potential Target against Alzheimer’s Disease, Frontiers in Neuroscience, 2016, 10, article 243, 10pp.
  4. ASO E., ANDRES-BENITO P., FERRER I. : Genetic deletion of CB1 cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model, Biochemical Pharmacology, 2018, DOI : 10.1016/j.bcp.2018.08.007
  5. BEDSE G., ROMANO A., LAVECCHIA A.M. et al. : The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer’s disease, Journal of Alzheimer’s Disease, 2015, 43, 4, 1115-1136.
  6. CALABRESE E.J., RUBIO-CASILLAS A. : Biphasic effects of THC in memory and cognition, European Journal of Clinical Investigation, 2018, 48, e12920. DOI: 10.1111/eci.12920
  1. CAMPBELL V.A. GOWRAN A. : Alzheimer’s disease ; taking the edge off with cannabinoids ?, British Journal of Pharmacology, 2007, 152, 5, 655-662. https://doi.org/10.1038/sj.bjp.0707446
  1. CURRAIS A., QUEHENBERGER O., ARMANDO A.M., DAUGHERTY D., MAHER P., SCHUBERT D. : Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids, NPJ, Aging and Mechanisms of Disease, 2016, 2, 16012. doi:10.1038/npjamd.2016.12
  1. EUBANKS L.M., ROGERTS C.J., : A Molecular Link Between the Active Component of Marijuana and Alzheimer’s Disease Pathology, Molecular Pharmacology, 2006, 3, 6, 773–777. doi:10.1021/mp060066m
  1. GROTENHERMEN F. : Chanvre en Médecine. Redécouverte d’une plante médicinale. Guide pratique des applications thérapeutiques du Cannabis, du THC et du CBD, Edition Solanacée, 2017, « Maladie d’Alzheimer » p 77.
  2. HERRMANN N., LANCTOT K. : La marijuana pour la maladie d’Alzheimer ?, CCNV/CCNA, http://ccna-ccnv.ca/fr/nouvelles/blogueurs-invites-la-marijuana-pour-la-maladie-dalzheimer
  3. JAYANT S. et al. : Pharmacological benefits of selective modulation of cannabinoid receptor type 2 (CB2) in experimental Alzheimer’s disease, Pharmacological and Biochemistry Behavior, 2016, 140, 39-50.
  4. KARL T., CHENG D., GARNER B., ARNOLD J.C. : The therapeutic potential of the endocannabinoid system for Alzheimer’s disease, Expert Opinion Therapeutic Targets, 2012, 16, 4, 407-420.
  5. PATEL S., SHUA-HAIM J.R., PASS M. : Safety and efficacy of dronabinol in the treatment of agitation in patients with Alzheimer’s disease with anorexia : A retrospective chart review, Abstract 11th International Conference of the IPA, 17-22 August 2003, Chicago.
  6. RAMIREZ B.G., BLAZQUEZ C et al. : Prevention of Alzheimer’s disease pathology by cannabinoids : neuroprotection mediated by blockade of microglial activation, Journal of Neuroscience, 2005, 23, 25, 8, 1904-1913.
  7. SHELEF A., BARAK Y., BERGER U., PALEACU D., TADGER S., PLOPSKY I., BARUCH Y. : Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia : An-Open Label, Add-On, Pilot Study, Journal of Alzheimer’s Disease, 2016, 51, 1, 15-19. Doi : 10.3233/JAD-150915
  1. VOLICER L., STELLY M, MORRIS J. et al. : Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s Disease, International Journal of Geriatric Psychiatry, 1997, 12, 913-919.

 

Bibliographie CANNABINOIDES et Maladies Neurodégénératives
Tags :
Categories : Bibliographies Cannabis therapeutique

Laisser un commentaire